Model-based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications. (PubMed, Clin Pharmacol Ther) - Sep 24, 2026 - P3 | "The MIDD approach provided an integrated and computationally efficient framework to characterize nivolumab SC/IV PK. Simulation-based analyses confirmed comparable benefit-risk profiles of nivolumab SC in adults across solid tumor indications and led to FDA approval of nivolumab SC in existing adult IV indications (except for nivolumab in combination with ipilimumab)."
Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Anna G Kondic; Elizabeth Gibson; Heather Vezina; Li Zhu; Yue Zhao; Zheyi Hu
|